Search results
Rapport Therapeutics director buys $9.5 million in company stock By Investing.com
Investing.com· 60 minutes agoDirector of Rapport Therapeutics, Inc. (NASDAQ:RAPP), James Healy, has recently made a substantial...
With 43% stake, Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) seems to have captured institutional...
Simply Wall St. via Yahoo Finance· 7 hours agoKey Insights Significantly high institutional ownership implies Y-mAbs Therapeutics' stock price is...
Has Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Impressive Stock Performance Got Anything to Do...
Simply Wall St. via Yahoo Finance· 1 day agoProtagonist Therapeutics (NASDAQ:PTGX) has had a great run on the share market with its stock up by...
Better Biotech Stock: Viking Therapeutics vs. Madrigal Pharmaceuticals
Motley Fool via Yahoo Finance· 11 hours agoViking Therapeutics (NASDAQ: VKTX) and Madrigal Pharmaceuticals (NASDAQ: MDGL) are highly prominent...
StockNews.com Downgrades ProQR Therapeutics (NASDAQ:PRQR) to Sell
ETF DAILY NEWS· 4 days agoProQR Therapeutics (NASDAQ:PRQR – Get Free Report) was downgraded by investment analysts at...
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Average Recommendation of “Buy” by Analysts
ETF DAILY NEWS· 23 hours agoDianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) has been assigned an average...
After Plunging -5.14% in 4 Weeks, Here's Why the Trend Might Reverse for Cerevel Therapeutics (CERE)
Zacks via Yahoo Finance· 11 hours agoCerevel Therapeutics (CERE) has become technically an oversold stock now, which implies exhaustion...
Tenaya Therapeutics (NASDAQ:TNYA) Coverage Initiated at William Blair
ETF DAILY NEWS· 16 hours agoEquities researchers at William Blair started coverage on shares of Tenaya Therapeutics (NASDAQ:TNYA – Get Free Report) in a report issued on Monday, Briefing.com reports.
It Looks Like Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO May Expect Their Salary To Be Put...
Simply Wall St. via Yahoo Finance· 5 days agoKey Insights Intellia Therapeutics will host its Annual General Meeting on 12th of June CEO John...
Halozyme Therapeutics Scores RS Rating Jump To 91
Investor's Business Daily· 3 days agoOn Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91. See if the biotech stock forms a new...